Adherence among HIV-positive injection drug users undergoing methadone treatment in Taiwan.
Adherence
Daily dose
HIV
Injection drug use
Methadone maintenance treatment
Retention
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
02 07 2020
02 07 2020
Historique:
received:
24
03
2020
accepted:
25
06
2020
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
22
12
2020
Statut:
epublish
Résumé
The study aims were to investigate adherence to methadone maintenance treatment (MMT) and to identify associated clinical factors in patients who inject drugs diagnosed with human immunodeficiency virus (HIV) infection in Taiwan. Data were from the National Health Surveillance System on HIV and the National Drug Treatment System on MMT. HIV-positive people who inject drugs (HIVPWID) were defined as the study population. Information obtained included age, sex, education, marital status, employment, methadone dose, and date of diagnosis of HIV infection. Adherence was defined as taking methadone for the past 90, 180 and 365 days, then categorized as high (> 90%), moderate (51 to 90%), or low (<=50%) adherent respectively. Of 1641 HIVPWID registered in the datasets from 2007 to 2012, 961 (58.56%) had received MMT. For HIVPWID evaluated at 90 days (n = 951), 271 (28.5%), 382 (40.2%), and 298 (31.3%) were classified as high, moderate, and low adherent respectively. For HIVPWID evaluated at 180 days (n = 936), 190 (20.3%), 349 (37.3%), and 397 (42.4%) were classified as high, moderate, and low adherent respectively. For HIVPWID evaluated at 365 days (n = 919), 133 (14.5%), 271 (29.5%), and 515 (56.0%) were classified as high, moderate, and low adherent respectively. After controlling for sociodemographics, results showed that methadone dose, location of MMT clinic, and date of HIV diagnosis were significantly associated with MMT adherence. Study findings underscore the importance to MMT adherence of methadone dosage, early diagnosis of patient's HIV infection, and area of patient residence.
Identifiants
pubmed: 32616019
doi: 10.1186/s12888-020-02764-0
pii: 10.1186/s12888-020-02764-0
pmc: PMC7331024
doi:
Substances chimiques
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
346Subventions
Organisme : NIAID NIH HHS
ID : P30 AI045008
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH097488
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069534
Pays : United States
Organisme : Ministry of Science and Technology, Taiwan
ID : 103-2410-H-003-022
Pays : International
Commentaires et corrections
Type : ErratumIn
Références
Auriacombe M, Moriceau S, Serre F, Denis C, Micoulaud-Franchi JA, de Sevin E, Bonhomme E, Bioulac S, Fatseas M, Philip P. Development and validation of a virtual agent to screen tobacco and alcohol use disorders. Drug Alcohol Depend. 2018;193:1–6.
doi: 10.1016/j.drugalcdep.2018.08.025
Barker B, Adams E, Wood E, Kerr T, DeBeck K, Dong H, Shoveller J, Montaner J, Milloy MJ. Engagement in maximally-assisted therapy and adherence to antiretroviral therapy among a cohort of indigenous people who use illicit drugs. AIDS Behav. 2019;23:1258–66.
doi: 10.1007/s10461-018-2226-y
Brief D, Bollinger J, Vielhauer AR, Berger-Greenstein MJ, Morgan JA, Brady EE, Buondonno SM, Keane LM, T. M. & For The Hiv/aids Treatment Adherence, Health Outcomes And Cost Study Group. Understanding the interface of HIV, trauma, post-trauMMTic stress disorder, and substance use and its implications for health outcomes. AIDS Care. 2004;16(sup1):97–120. https://doi.org/10.1080/09540120412301315259 .
doi: 10.1080/09540120412301315259
Chou YC, Shih SF, Tsai WD, Li CS, Xu K, Lee TS. Improvement of quality of life in methadone treatment patients in northern Taiwan: a follow-up study. BMC Psychiatry. 2013;13:190.
doi: 10.1186/1471-244X-13-190
Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005;100:1496–509.
doi: 10.1111/j.1360-0443.2005.01232.x
Dvoriak S, Karachevsky A, Chhatre S, Booth R, Metzger D, Schumacher J, Chychula N, Pecoraro A, Woody G. Methadone maintenance for HIV positive and HIV negative patients in Kyiv: acceptability and treatment response. Drug Alcohol Depend. 2014;137:62–7.
doi: 10.1016/j.drugalcdep.2014.01.008
Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93:1051–5.
doi: 10.1136/hrt.2006.100180
Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of SysteMMTic Reviews. 2011;8:Cd004145.
Groh K, Audet CM, Baptista A, Sidat M, Vergara A, Vermund SH, Moon TD. Barriers to antiretroviral therapy adherence in rural Mozambique. BMC Public Health. 2011;11:650.
doi: 10.1186/1471-2458-11-650
Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82:223–7.
doi: 10.1111/j.1600-0447.1990.tb03057.x
Hayashi K, Ti L, Ayutthaya PPN, Suwannawong P, Kaplan K, Small W, Kerr T. Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study. Harm Reduct Journal. 2017;14:63.
doi: 10.1186/s12954-017-0189-3
Jiang H, Cao X, Wang C, Luo W, Li J, Rou K, Zhang B, Fang Y, Li C, Wu Z. Study on the adherence and related determinants among HIV-positive clients under methadone maintenance treatment in Dali,Yunnan province from 2005 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2014;35:255–8.
pubmed: 24831621
Kourounis G, Richards BD, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1–8.
doi: 10.1016/j.drugalcdep.2015.12.021
Lee TS, Shen HC, Wu WH, Huang CW, Yen MY, Wang BE, Chuang P, Shih CY, Chou YC, Liu YL. Clinical characteristics and risk behavior as a function of HIV status among heroin users enrolled in methadone treatment in northern Taiwan. Substance Abuse Treatment Prevention Policy. 2011;6:6.
doi: 10.1186/1747-597X-6-6
Lin CK, Hung CC, Peng CY, Chao E, Lee TS. Factors associated with methadone treatment duration: a cox regression analysis. PLoS One. 2015;10:e0123687.
doi: 10.1371/journal.pone.0123687
Liu D, Gu J, Xu H, Hao C, Jiao M, Zhang X, Zhao Y, Andrew B, Hao Y. Club drugs and alcohol abuse predicted dropout and poor adherence among methadone maintenance treatment patients in Guangzhou, China. AIDS Care. 2017;29:458–63.
doi: 10.1080/09540121.2016.1259452
Marienfeld C, Liu P, Wang X, Schottenfeld R, Zhou W, Chawarski MC. Evaluation of an implementation of methadone maintenance treatment in China. Drug Alcohol Depend. 2015;157:60–7.
doi: 10.1016/j.drugalcdep.2015.10.001
Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher-dose methadone. J Psychoactive Drugs. 1999;31:95–102.
doi: 10.1080/02791072.1999.10471730
McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis. 2005;41(Suppl 1):S89–95.
doi: 10.1086/429503
McGlothlin WH, Anglin MD. Shutting off methadone. Costs and benefits. Arch Gen Psychiatry. 1981;38:885–92.
doi: 10.1001/archpsyc.1981.01780330043004
McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689–95.
doi: 10.1001/jama.284.13.1689
Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485–8.
doi: 10.1016/S0140-6736(79)91550-2
Olley B, Seedat S, Stein DJ. Persistence of psychiatric disorders in a cohort of HIV/AIDS patients in South Africa: a 6-month follow-up study. J PsychosoMMTic Res. 2006;61:479–84.
doi: 10.1016/j.jpsychores.2006.03.010
Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84:188–94.
doi: 10.1016/j.drugalcdep.2006.02.003
Reddon H, Milloy MJ, Simo A, Montaner J, Wood E, Kerr T. Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users. AIDS Behav. 2014;18:740–6.
doi: 10.1007/s10461-013-0584-z
Reid G, Sharma M, Higgs P. The long winding road of opioid substitution therapy implementation in South-East Asia: challenges to scale up. J Public Health Res. 2014;3:204.
doi: 10.4081/jphr.2014.204
Roux P, Lions C, Michel L, Cohen J, Mora M, Marcellin F, Spire B, Morel A, Carrieri PM, Karila L. Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians. Curr Pharm Des. 2014;20:4097–105.
doi: 10.2174/13816128113199990623
Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018;113:656–67.
doi: 10.1111/add.14059
Sharma V, Chamroonswasdi K, Srisorrachatr S. Rate of adhernce to and factors associated with methadone maintenance treatment program (MMTP) compliance among injecting drug use patients in Nepal. Southeast Asian J Trop Med Public Health. 2016;47:287–98.
pubmed: 27244967
Shen J, Wang M, Wang X, Zhang G, Guo J, Li X, Li J. Predictors of poor adherence to methadone maintenance treatment in Yunnan Province, China. J Addict Med. 2016;10:40–5.
doi: 10.1097/ADM.0000000000000180
Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000–5.
doi: 10.1001/jama.281.11.1000
Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction. 2005;100:150–8.
doi: 10.1111/j.1360-0443.2004.00963.x
Tran BX, Nguyen LH, Tran TT, Latkin CA. Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients. PLoS One. 2018;13:e0190941.
doi: 10.1371/journal.pone.0190941
Van Nguyen H, Nguyen HL, Mai HT, Le HQ, Tran BX, Hoang CD, Le HT, Nguyen CT, Tran TD, Latkin CA, Vu TM. StigMMTization among methadone maintenance treatment patients in mountainous areas in northern Vietnam. Harm Reduct J. 2017;14:1.
doi: 10.1186/s12954-016-0127-9
Volkow ND, Montaner J. The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff. 2011;30:1411–9.
doi: 10.1377/hlthaff.2011.0663
World Health Organization, Regional Office for South-East Asia. Operational guidelines for the management of opioid dependence in the South-East Asia region. New Delhi: WHO Regional Office for South-East Asia; 2008.
Zhang L, Chow EP, Zhuang X, Liang Y, Wang Y, Tang C, Ling L, Tucker JD, Wilson DP. Methadone maintenance treatment participant retention and behavioural effectiveness in China: a systeMMTic review and meta-analysis. PLoS One. 2013;8:e68906.
doi: 10.1371/journal.pone.0068906
Zhou K, Li H, Wei X, Li X, Zhuang G. Medication adherence in patients undergoing methadone maintenance treatment in Xi'an, China. J Addict Med. 2017;11:28–33.
doi: 10.1097/ADM.0000000000000263